Evommune, Inc.
1452 Aura Way
Los Altos
CA
94024
United States
Website: https://www.evommune.com/
Email: business.inquiries@evommune.com
About Evommune, Inc.
It is estimated that 60% of Americans live with at least one chronic inflammatory disease and it is expected that the prevalence will increase steadily over the next 30 years. Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a significantly reduced quality of life. Evommune’s focus is the discovery and development of unique therapies that help patients with chronic inflammatory diseases. We are evaluating multiple known and novel targets addressing both adaptive and innate immunity. Utilizing a unique screening platform, we identify molecules that are differentiated and that have a greater probability of being effective in treating patients. Our technology, coupled with a team with an extensive track record of successfully developing new medicines, will help accelerate the R&D process so that we can more quickly serve people with inflammatory diseases.
3 articles with Evommune, Inc.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases
11/16/2021
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced that Hans Hofland, senior vice president, research, will present at the 42nd Annual Meeting of the American College of Toxicology and the 5th Annual Dermatology Drug Development Summit for Inflammatory Diseases this week.
-
Los Altos, Calif.-based Evommune closed on a Series A financing round worth $83 million. The financing round included Andera Partners, LSP, Pivotal bioVenture Partners.